/RLYB
RLYB Stock - Rallybio Corporation
Healthcare|BiotechnologyNASDAQ
$0.79+0.93%
+$0.01 (+0.93%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.86
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RLYB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.78 – $0.79
TARGET (TP)$0.90
STOP LOSS$0.72
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.04
52W High$1.08
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $636,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $636,000 | N/A | N/A | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-60,496,000 | $-78,932,000 | $-67,884,000 | $-45,648,000 | $-25,303,000 |
| Net Income | $-57,775,000 | $-74,564,000 | $-66,654,000 | $-47,013,000 | $-26,447,000 |
| Net Margin | -9084.1% | N/A | N/A | N/A | N/A |
| EPS | $-1.33 | $-1.84 | $-2.09 | $-1.46 | $-1.19 |
Company Overview
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
3
60%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$14
Average Target
↑ 1731.2% Upside
Now
$2
Low
$14
Average
$21
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 9th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| May 15th 2024 | JP Morgan | Downgrade | Neutral | - |
| February 7th 2024 | Jefferies | Downgrade | Hold | $1.5← $7 |
| April 17th 2023 | H.C. Wainwright | Initiation | Buy | $18 |
| April 10th 2023 | Wedbush | Initiation | Outperform | $17 |
| December 9th 2022 | JP Morgan | Initiation | Overweight | $21 |
Earnings History & Surprises
RLYBBeat Rate
61%
Last 18 quarters
Avg Surprise
+9.7%
EPS vs Estimate
Beats / Misses
11/4
3 met exactly
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
-13.6%
$-0.50vs$-0.44
Q2 24
+6.0%
$-0.47vs$-0.50
Q3 24
+11.9%
$-0.37vs$-0.42
Q4 24
+27.8%
$-0.26vs$-0.36
Q1 25
+7.4%
$-0.25vs$-0.27
Q2 25
0.0%
$-0.21vs$-0.21
Q3 25
-12.8%
$-0.22vs$-0.20
Q4 25
+44.0%
$-0.14vs$-0.25
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.25 | $-0.14 | +44.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.20 | $-0.22 | -12.8% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.21 | $-0.21 | 0.0% | = MET |
Q1 2025 | Mar 13, 2025 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.36 | $-0.26 | +27.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.42 | $-0.37 | +11.9% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.50 | $-0.47 | +6.0% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.44 | $-0.50 | -13.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.51 | $-0.45 | +11.8% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.48 | $-0.46 | +4.2% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.50 | $-0.43 | +14.0% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.63 | $-0.46 | +27.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.54 | $-0.60 | -11.1% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.61 | $-0.57 | +6.6% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.48 | $-0.48 | 0.0% | = MET |
Q1 2022 | Mar 15, 2022 | $-0.39 | $-0.42 | -7.7% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.89 | $-0.37 | +58.4% | ✓ BEAT |
Q3 2021 | Sep 9, 2021 | $-2.80 | $-2.80 | 0.0% | = MET |
Q3 2021 | Jul 30, 2021 | — | $-0.60 | — | — |
Latest News
UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate
📈 PositiveBenzinga•Nov 6, 2025, 02:35 PM
Rallybio Q3 EPS $0.36 Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate
📈 PositiveBenzinga•Nov 6, 2025, 01:25 PM
Rallybio Completes Dosing For First Cohort In Phase 1 Confirmatory PK/PD Study Of RLYB116 Its Once-Weekly, Small-Volume, Subcutaneous C5 Inhibitor Being Developed To Treat Rare Diseases
📈 PositiveBenzinga•Sep 25, 2025, 12:05 PM
RLYB stock has given up its prior gain. Rallybio shares were trading higher after the company received a $12.5M equity milestone payment from Recursion following the initiation of preclinical studies for REV102.
➖ NeutralBenzinga•Sep 3, 2025, 06:55 PM•Also:
Rallybio shares are trading higher after the company received a $12.5M equity milestone payment from Recursion following the initiation of preclinical studies for REV102.
📈 PositiveBenzinga•Sep 3, 2025, 12:02 PM•Also:
Rallybio Receives $12.5M Equity Milestone Payment From Recursion, Triggered By Initiation Of Preclinical Studies For REV102
📈 PositiveBenzinga•Sep 3, 2025, 12:02 PM•Also:
Recursion to buy Rallybio's ownership in jointly developed bone disorder drug
📈 PositiveSeeking Alpha•Jul 8, 2025, 12:39 PM•Also:
Frequently Asked Questions about RLYB
What is RLYB's current stock price?
Rallybio Corporation (RLYB) is currently trading at $0.79 per share. The stock has moved +0.93% today.
What is the analyst price target for RLYB?
No analyst price targets are currently available for this stock.
What sector is Rallybio Corporation in?
Rallybio Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RLYB's market cap?
Rallybio Corporation has a market capitalization of $0.03 billion, making it a small-cap company.
Does RLYB pay dividends?
No, Rallybio Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to RLYB for comparison